Pharmaceutical intermediates are drugs used as raw materials in the production of bulk drugs. Moreover, they are widely used to refer to a material created during the synthesis of an active pharmaceutical ingredient (API) before the processing of becoming an API. Pharmaceutical intermediates are usually formed using high-grade raw materials. These intermediates are widely used in the pharmaceutical and cosmetic industries. The rising demand in these industries is expanding the global pharmaceutical intermediates market. Pharmaceutical intermediates are popularly used for research and development in the pharmaceutical industry. The pharmaceutical intermediates are increasingly being produced using raw materials such as coal tar or petroleum to manufacture pesticides, pharmaceuticals, resins, additives, plasticizers, etc. However, several intermediates can be produced in organic synthesis, and be used in creating various drugs and products. The increasing demand for research and development across the world is propelling the global pharmaceutical intermediates market during the forecast period.
Intermediates can be defined as semi-finished products that are intermediate products of certain products. In simpler words, to produce a product, it can be produced from intermediates to save costs. Pharmaceutical production needs a large number of specific chemicals that were originally produced by the pharmaceutical industry. However, with the expansion of social labor division and the evolution of production technology, the pharmaceutical industry can transfer the production of required pharmaceutical intermediates to chemical enterprises. Pharmaceutical intermediates are exquisite chemical products. The production of pharmaceutical intermediates has grown vastly in the international chemical industry. The growing chemical industry is driving demand for pharmaceutical intermediates across the world. The pharmaceutical intermediates are produced on demand for bulk and custom productions.
The outbreak of the novel COVID-19 disease led to a global pandemic that poses a serious risk to the macro economy through the halt in production activities, interruptions of people's movement, and disruption in supply chains. The crisis has had critical effects on the global healthcare industry and the pharmaceutical sector, which are expected to last long. The pharmaceutical industry will be needing appropriate planning to reduce its socio-economic burden in the upcoming future. As the virus began to spread worldwide in 2020, the pharmaceutical industry supported governments to help provide with the rising demand. Pharmaceutical ingredients raised in demand for research and development of the cure. On the other hand, pharmaceutical sectors struggled to maintain natural market flow, as the pandemic affected the access to essential medicines due to increased consumer storage. With the evaluation of the pharmaceutical system challenges at the global level, the report displays the situation analysis of the pharmaceutical intermediates market in developing countries with emerging pharmaceutical markets.
The spread of the virus has resulted in increased hospitalization with COVID-19 patients that led to a shortage of medicinal storage. Globally, many government authorities announced shortages for several medicines, including the potential treatments for COVID-19. The pandemic can be associated with various short and long-term impacts on the pharmaceutical intermediates market, mainly due to restrictions in the global supply chain resulting in a lack of raw materials. Recognizing these impacts may guide businesses in evidence-informed preparation and decision-making to fight associated difficulties. Various other industries had critical losses with the restrictions in manufacturing and selling. Several end users of pharmaceutical intermediates suffered from shutdowns, project delays, insufficient raw materials, and workforce, etc. Nevertheless, with markets being restored in many countries, and pandemic near its end, end-use industries in the pharmaceutical intermediates market, including CMOs and CROs, are anticipating rise in demand post-COVID-19 pandemic.
The pharmaceutical industry is constantly unfolding and reshaping itself. Various pharmaceutical organizations and major market players are adapting modifications in pharmaceutical intermediate businesses with their rising demand. As pharmaceutical and chemical activities stretch around the globe, innovations are the key focus of manufacturers, and the demand for pharmaceutical intermediates companies is on the rise. Due to the implementation of standardized pharmaceutical activities, good manufacturing practices (GMP) in pharmaceutical corporations, the global pharmaceutical intermediates market is expected to grow in the upcoming future. Major chemical and pharmaceutical manufacturers compete to capture the positions in the pharmaceutical intermediates market. Fulfilling consumer demand for speed, innovation, low cost, and quality amid rising competition and unpredictable market are focus points. However, the onset of new players is making it difficult to shine, which drives the need for outsourcing chemical services at all points, along the drug development pipeline.
With growing pharmaceutical manufacturers and consumers in the U.S. and Canada, North America is projected to hold a major share of the pharmaceutical intermediate market. In addition, the rising prevalence of several contagious and chronic diseases has raised the demand for pharmaceuticals, which is most likely to promote the growth of the pharmaceutical intermediates market over the projected period. Moreover, the presence of major market players in North America is also contributing to the expansion of the pharmaceutical intermediates market in North America. Furthermore, rise in R&D activities and increase in investments in these activities from governments and major players in Europe are likely to drive the market in North America. Additionally, the improved demand for advanced pharmaceutical products is expected to boost the pharmaceutical intermediates market during the forecast period.
The world is witnessing an increasing number of diseases and a rising number of patients every year. In addition, the number of physician visits for infectious and parasitic diseases has rapidly raised in millions, creating the demand for numerous pharmaceutical products. High spending on R&D and advancements in innovative therapies are anticipated to improve the growth rate of the pharmaceutical intermediates market in the near future. However, strict regulatory policies for manufacturers for product quality will slow down the growth rate. Nevertheless, with increase in healthcare expenditure and rise in manufacturer focus on research & development, the global pharmaceutical intermediates market is projected to expand at a CAGR of ~6% from 2021 to 2031.
Analysts' Viewpoint
The demand for pharmaceutical intermediates majorly depends on the rise in the demand for essential drugs to treat chronic diseases. The growing prevalence of contagious diseases, principally in Southeast Asia, is likely to fuel the demand for APIs in the following years, ultimately propelling the pharmaceutical intermediates market. Moreover, advancements in technologies such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification are increasing the demand for pharmaceutical intermediates for research purposes. Hence, owing to rising production and research exercises in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to witness a constant growth during the projected period.
Pharmaceutical intermediates market to reach valuation of US$ 53.4 Bn by 2031
Pharmaceutical intermediates market is projected to expand at a CAGR of ~6% from 2021 to 2031
Pharmaceutical intermediates market is driven by rise in healthcare expenditure and focus on research & development
North America is expected to account for a significant share of the global pharmaceutical intermediates market during the forecast period
Key players in the global pharmaceutical intermediates market include BASF SE, Lonza Group, Evonik Industries AG, Cambrex Corporation, DSM, Aceto
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmaceutical Intermediates Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Pharmaceutical Intermediates Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events (mergers and acquisitions, new product development, etc.)
5.3. Pharmaceutical Intermediates Products/Brands List
6. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
6.2.1. Bulk Drug Intermediate
6.2.1.1. Chiral Intermediate
6.2.1.2. Achiral Intermediate
6.2.2. Custom Intermediate
6.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Product
7. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
7.2.1. Cardiology
7.2.2. Oncology
7.2.3. Endocrinology
7.2.4. Infectious Diseases
7.2.5. Orthopedics
7.2.6. Neurology
7.2.7. Gastroenterology
7.2.8. Dermatology
7.2.9. Inflammatory & Pain Management
7.2.10. Ophthalmology
7.2.11. Others
7.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Application
8. Global Pharmaceutical Intermediates Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
8.2.1. Pharmaceutical & Biotechnology Companies
8.2.2. CROs & CMOs
8.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user
9. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Pharmaceutical Intermediates Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Region
10. North America Pharmaceutical Intermediates Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
10.2.1. Bulk Drug Intermediate
10.2.1.1. Chiral Intermediate
10.2.1.2. Achiral Intermediate
10.2.2. Custom Intermediate
10.3. North America Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
10.3.1. Cardiology
10.3.2. Oncology
10.3.3. Endocrinology
10.3.4. Infectious Diseases
10.3.5. Orthopedics
10.3.6. Neurology
10.3.7. Gastroenterology
10.3.8. Dermatology
10.3.9. Inflammatory & Pain Management
10.3.10. Ophthalmology
10.3.11. Others
10.4. North America Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
10.4.1. Pharmaceutical & Biotechnology Companies
10.4.2. CROs & CMOs
10.5. North America Pharmaceutical Intermediates Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Pharmaceutical Intermediates Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Pharmaceutical Intermediates Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
11.2.1. Bulk Drug Intermediate
11.2.1.1. Chiral Intermediate
11.2.1.2. Achiral Intermediate
11.2.2. Custom Intermediate
11.3. Europe Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
11.3.1. Cardiology
11.3.2. Oncology
11.3.3. Endocrinology
11.3.4. Infectious Diseases
11.3.5. Orthopedics
11.3.6. Neurology
11.3.7. Gastroenterology
11.3.8. Dermatology
11.3.9. Inflammatory & Pain Management
11.3.10. Ophthalmology
11.3.11. Others
11.4. Europe Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
11.4.1. Pharmaceutical & Biotechnology Companies
11.4.2. CROs & CMOs
11.5. Europe Pharmaceutical Intermediates Market Value Forecast by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Pharmaceutical Intermediates Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Pharmaceutical Intermediates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
12.2.1. Bulk Drug Intermediate
12.2.1.1. Chiral Intermediate
12.2.1.2. Achiral Intermediate
12.2.2. Custom Intermediate
12.3. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
12.3.1. Cardiology
12.3.2. Oncology
12.3.3. Endocrinology
12.3.4. Infectious Diseases
12.3.5. Orthopedics
12.3.6. Neurology
12.3.7. Gastroenterology
12.3.8. Dermatology
12.3.9. Inflammatory & Pain Management
12.3.10. Ophthalmology
12.3.11. Others
12.4. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
12.4.1. Pharmaceutical & Biotechnology Companies
12.4.2. CROs & CMOs
12.5. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Pharmaceutical Intermediates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
13.2.1. Bulk Drug Intermediate
13.2.1.1. Chiral Intermediate
13.2.1.2. Achiral Intermediate
13.2.2. Custom Intermediate
13.3. Latin America Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
13.3.1. Cardiology
13.3.2. Oncology
13.3.3. Endocrinology
13.3.4. Infectious Diseases
13.3.5. Orthopedics
13.3.6. Neurology
13.3.7. Gastroenterology
13.3.8. Dermatology
13.3.9. Inflammatory & Pain Management
13.3.10. Ophthalmology
13.3.11. Others
13.4. Latin America Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
13.4.1. Pharmaceutical & Biotechnology Companies
13.4.2. CROs & CMOs
13.5. Latin America Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Pharmaceutical Intermediates Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Pharmaceutical Intermediates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
14.2.1. Bulk Drug Intermediate
14.2.1.1. Chiral Intermediate
14.2.1.2. Achiral Intermediate
14.2.2. Custom Intermediate
14.3. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
14.3.1. Cardiology
14.3.2. Oncology
14.3.3. Endocrinology
14.3.4. Infectious Diseases
14.3.5. Orthopedics
14.3.6. Neurology
14.3.7. Gastroenterology
14.3.8. Dermatology
14.3.9. Inflammatory & Pain Management
14.3.10. Ophthalmology
14.3.11. Others
14.4. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
14.4.1. Pharmaceutical & Biotechnology Companies
14.4.2. CROs & CMOs
14.5. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2020
15.3. Company Profiles
15.3.1. BASF SE
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Lonza Group
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Evonik Industries AG
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Cambrex Corporation
15.3.4.1. Company Description
15.3.4.2. Business Overview
15.3.4.3. Strategic Overview
15.3.4.4. SWOT Analysis
15.3.5. DSM
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. Aceto
15.3.6.1. Company Description
15.3.6.2. Business Overview
15.3.6.3. Strategic Overview
15.3.6.4. SWOT Analysis
15.3.7. Albemarle Corporation
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Vertellus
15.3.8.1. Company Description
15.3.8.2. Business Overview
15.3.8.3. Strategic Overview
15.3.8.4. SWOT Analysis
15.3.9. Chemcon Speciality Chemicals Ltd.
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. chiracon GmbH
15.3.10.1. Company Description
15.3.10.2. Business Overview
15.3.10.3. Strategic Overview
15.3.10.4. SWOT Analysis
15.3.11. A. R. Life Sciences Private Limited
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. Strategic Overview
15.3.11.4. SWOT Analysis
List of Tables
Table 01: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 03: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 09: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 10: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 16: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 21: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 22: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 27: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 28: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 33: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 34: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 35: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Pharmaceutical Intermediates Market Value Share, by Product, 2020
Figure 03: Global Pharmaceutical Intermediates Market Value Share, by Application, 2020
Figure 04: Global Pharmaceutical Intermediates Market Value Share, by End-user, 2020
Figure 05: Global Pharmaceutical Intermediates Market Value Share, by Region, 2020
Figure 06: Global Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 07: Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 08: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Bulk Drug Intermediate, 2017–2031
Figure 09: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Custom Intermediate, 2017–2031
Figure 10: Global Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 11: Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 12: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Cardiology, 2017–2031
Figure 13: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Oncology, 2017–2031
Figure 14: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Endocrinology, 2017–2031
Figure 15: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Infectious Diseases, 2017–2031
Figure 16: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Orthopedics, 2017–2031
Figure 17: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Neurology, 2017–2031
Figure 18: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Gastroenterology, 2017–2031
Figure 19: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Dermatology, 2017–2031
Figure 20: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Others, 2017–2031
Figure 21: Global Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 22: Global Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Figure 23: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031
Figure 24: Global Pharmaceutical Intermediates Market Revenue (US$ Mn), by CROs & CMOs, 2017–2031
Figure 25: Global Pharmaceutical Intermediates Market Value Share Analysis, by Region, 2020 and 2031
Figure 26: Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Region, 2021–2031
Figure 27: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: North America Pharmaceutical Intermediates Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 29: North America Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 30: North America Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 31: North America Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 32: North America Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 33: North America Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 34: North America Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 35: North America Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Figure 36: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Europe Pharmaceutical Intermediates Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 38: Europe Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Europe Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 40: Europe Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 41: Europe Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 42: Europe Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 43: Europe Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 44: Europe Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Figure 45: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Asia Pacific Pharmaceutical Intermediates Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 47: Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 48: Asia Pacific Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 49: Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 50: Asia Pacific Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 51: Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 52: Asia Pacific Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 53: Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Figure 54: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 55: Latin America Pharmaceutical Intermediates Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 56: Latin America Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 57: Latin America Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 58: Latin America Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 59: Latin America Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 60: Latin America Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 61: Latin America Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 62: Latin America Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Figure 63: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, 2017–2031
Figure 64: Middle East & Africa Pharmaceutical Intermediates Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 65: Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 66: Middle East & Africa Pharmaceutical Intermediates Market Value Share Analysis, by Product, 2020 and 2031
Figure 67: Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis, by Product, 2021–2031
Figure 68: Middle East & Africa Pharmaceutical Intermediates Market Value Share Analysis, by Application, 2020 and 2031
Figure 69: Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis, by Application, 2021–2031
Figure 70: Middle East & Africa Pharmaceutical Intermediates Market Value Share Analysis, by End-user, 2020 and 2031
Figure 71: Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pharmaceutical Intermediates Market Forecast Report, 2021 - 2031
